{"id":2408,"date":"2026-01-06T08:30:38","date_gmt":"2026-01-06T13:30:38","guid":{"rendered":"https:\/\/9bio.ca\/?p=2408"},"modified":"2026-06-01T10:17:00","modified_gmt":"2026-06-01T14:17:00","slug":"9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery","status":"publish","type":"post","link":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/","title":{"rendered":"9Bio Th\u00e9rapeutiques approuv\u00e9e pour le plus haut niveau de cr\u00e9dits Microsoft for Startups afin d\u2019acc\u00e9l\u00e9rer la d\u00e9couverte de th\u00e9rapies biologiques propuls\u00e9e par l\u2019IA"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Qu\u00e9bec, QC, le 6 janvier 2026<\/strong> \u2013 9Bio Th\u00e9rapeutiques, une entreprise de biotechnologie d\u00e9veloppant des th\u00e9rapies biologiques de nouvelle g\u00e9n\u00e9ration s\u00e9lectives pour les tumeurs, a annonc\u00e9 aujourd\u2019hui avoir \u00e9t\u00e9 approuv\u00e9e pour le plus haut niveau de cr\u00e9dits Azure disponible dans le cadre du programme Microsoft for Startups, donnant acc\u00e8s \u00e0 150 000 $ US en cr\u00e9dits infonuagiques pour soutenir le d\u00e9veloppement continu de sa plateforme computationnelle d\u2019ing\u00e9nierie des prot\u00e9ines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ce soutien aidera 9Bio \u00e0 accro\u00eetre ses activit\u00e9s de d\u00e9couverte propuls\u00e9es par l\u2019IA et guid\u00e9es par la structure, notamment l\u2019exploration num\u00e9rique \u00e0 grande \u00e9chelle de variants d\u2019anticorps et de prot\u00e9ines, la mod\u00e9lisation mol\u00e9culaire, l\u2019optimisation des candidats et la priorisation des candidats th\u00e9rapeutiques fond\u00e9e sur les donn\u00e9es avant les essais en laboratoire.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00ab L\u2019acc\u00e8s \u00e0 des ressources Microsoft Azure \u00e9largies repr\u00e9sente une \u00e9tape importante pour 9Bio alors que nous continuons \u00e0 b\u00e2tir une voie plus pr\u00e9dictive vers des th\u00e9rapies biologiques s\u00e9lectives pour la maladie \u00bb, a d\u00e9clar\u00e9 Henrique de Carvalho, cofondateur et chef de la direction de 9Bio Therapeutics. \u00ab Ce soutien nous permet d\u2019accro\u00eetre notre capacit\u00e9 computationnelle tout en pr\u00e9servant du capital pour les activit\u00e9s critiques de validation exp\u00e9rimentale et de d\u00e9veloppement th\u00e9rapeutique. \u00bb<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La plateforme de 9Bio est con\u00e7ue pour cr\u00e9er des th\u00e9rapies biologiques capables d\u2019agir plus pr\u00e9cis\u00e9ment l\u00e0 o\u00f9 elles sont n\u00e9cessaires, avec un accent initial sur des programmes en oncologie o\u00f9 les cibles associ\u00e9es aux tumeurs peuvent \u00e9galement \u00eatre pr\u00e9sentes dans les tissus sains. En combinant conception computationnelle, biologie structurale et validation exp\u00e9rimentale, l\u2019entreprise vise \u00e0 d\u00e9velopper des th\u00e9rapies diff\u00e9renci\u00e9es \u00e0 base d\u2019anticorps, dot\u00e9es d\u2019une meilleure s\u00e9lectivit\u00e9 tumorale, d\u2019une s\u00e9curit\u00e9 accrue et d\u2019un potentiel th\u00e9rapeutique am\u00e9lior\u00e9.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le soutien de Microsoft for Startups sera utilis\u00e9 pour renforcer l\u2019infrastructure infonuagique de 9Bio et acc\u00e9l\u00e9rer le d\u00e9veloppement de ses flux de travail computationnels propri\u00e9taires. Ces capacit\u00e9s devraient soutenir \u00e0 la fois les programmes th\u00e9rapeutiques internes de l\u2019entreprise et de futures collaborations avec des partenaires biopharmaceutiques, acad\u00e9miques et translationnels travaillant sur des th\u00e9rapies complexes \u00e0 base de prot\u00e9ines.<\/p>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\"><strong>&#8211; 30 &#8211;<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c0 propos de 9Bio Th\u00e9rapeutiques<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">9Bio est une entreprise de biotechnologie d\u00e9di\u00e9e au d\u00e9veloppement de th\u00e9rapies oncologiques innovantes. Notre plateforme de biologie structurale guid\u00e9e par l'IA int\u00e8gre des contextes anatomiques et biochimiques pour concevoir des m\u00e9dicaments ciblant s\u00e9lectivement les tumeurs. Gr\u00e2ce \u00e0 cette approche, nous d\u00e9veloppons des traitements sp\u00e9cifiquement dirig\u00e9s contre les tumeurs, tout en pr\u00e9servant les tissus sains, am\u00e9liorant ainsi la s\u00e9curit\u00e9, l\u2019efficacit\u00e9 et ouvrant la voie \u00e0 des modalit\u00e9s th\u00e9rapeutiques jusqu\u2019ici sous-exploit\u00e9es. Notre pipeline comprend des anticorps anti-PD-L1 conditionnels et s\u00e9lectifs pour les tumeurs, pouvant servir de bras strat\u00e9giques dans des constructions multisp\u00e9cifiques, ainsi que des ADCs bisp\u00e9cifiques con\u00e7us pour cibler des cancers chimior\u00e9sistants et m\u00e9tastatiques.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c0 propos de Microsoft for Startups<\/strong><\/p>\n\n\n\n<p class=\"has-theme-palette-9-color has-text-color has-link-color wp-elements-a04229167a4453c9f625537a3694c5c9 wp-block-paragraph\">Microsoft for Startups est un programme mondial con\u00e7u pour aider les entreprises en d\u00e9marrage \u00e0 d\u00e9velopper, lancer et faire \u00e9voluer leurs activit\u00e9s sur Azure. Le programme offre aux startups admissibles un acc\u00e8s \u00e0 des cr\u00e9dits infonuagiques, \u00e0 des mod\u00e8les d\u2019IA, \u00e0 des outils de d\u00e9veloppement, \u00e0 des ressources techniques et \u00e0 un soutien \u00e0 la commercialisation. Gr\u00e2ce au programme, les startups peuvent d\u00e9bloquer jusqu\u2019\u00e0 150 000 $ US en cr\u00e9dits Azure \u00e0 mesure qu\u2019elles d\u00e9montrent des progr\u00e8s, une adoption et une utilisation soutenue d\u2019Azure.<\/p>","protected":false},"excerpt":{"rendered":"<p>9Bio Th\u00e9rapeutiques a \u00e9t\u00e9 approuv\u00e9e pour le plus haut niveau de cr\u00e9dits Azure disponible dans le cadre du programme Microsoft for Startups, donnant acc\u00e8s \u00e0 150 000 $ US en cr\u00e9dits infonuagiques afin d\u2019acc\u00e9l\u00e9rer sa plateforme de d\u00e9couverte computationnelle guid\u00e9e par la structure.<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-2408","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>9Bio Therapeutics Approved for Highest Microsoft for Startups Credit Tier to Accelerate AI-Enabled Biologics Discovery - 9Bio Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"9Bio Therapeutics Approved for Highest Microsoft for Startups Credit Tier to Accelerate AI-Enabled Biologics Discovery - 9Bio Therapeutics\" \/>\n<meta property=\"og:description\" content=\"9Bio Therapeutics has been approved for the highest Azure credit tier available through Microsoft for Startups, providing access to US$150,000 in cloud credits to accelerate its structure-guided computational discovery platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"9Bio Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T13:30:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T14:17:00+00:00\" \/>\n<meta name=\"author\" content=\"Henrique de Carvalho\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Henrique de Carvalho\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\\\/\"},\"author\":{\"name\":\"Henrique de Carvalho\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/person\\\/eda3764256a793b2350112b46b0169a8\"},\"headline\":\"9Bio Therapeutics Approved for Highest Microsoft for Startups Credit Tier to Accelerate AI-Enabled Biologics Discovery\",\"datePublished\":\"2026-01-06T13:30:38+00:00\",\"dateModified\":\"2026-06-01T14:17:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\\\/\"},\"wordCount\":403,\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\\\/\",\"name\":\"9Bio Therapeutics Approved for Highest Microsoft for Startups Credit Tier to Accelerate AI-Enabled Biologics Discovery - 9Bio Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\"},\"datePublished\":\"2026-01-06T13:30:38+00:00\",\"dateModified\":\"2026-06-01T14:17:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/9biotx.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"9Bio Therapeutics Approved for Highest Microsoft for Startups Credit Tier to Accelerate AI-Enabled Biologics Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"name\":\"9Bio Therapeutics\",\"description\":\"Engineering Biological Possibilities\",\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/9biotx.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\",\"name\":\"9Bio Therapeutics\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"contentUrl\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"width\":200,\"height\":80,\"caption\":\"9Bio Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/9bio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/person\\\/eda3764256a793b2350112b46b0169a8\",\"name\":\"Henrique de Carvalho\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"caption\":\"Henrique de Carvalho\"},\"sameAs\":[\"https:\\\/\\\/9bio.ca\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"9Bio Therapeutics Approved for Highest Microsoft for Startups Credit Tier to Accelerate AI-Enabled Biologics Discovery - 9Bio Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/","og_locale":"fr_CA","og_type":"article","og_title":"9Bio Therapeutics Approved for Highest Microsoft for Startups Credit Tier to Accelerate AI-Enabled Biologics Discovery - 9Bio Therapeutics","og_description":"9Bio Therapeutics has been approved for the highest Azure credit tier available through Microsoft for Startups, providing access to US$150,000 in cloud credits to accelerate its structure-guided computational discovery platform.","og_url":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/","og_site_name":"9Bio Therapeutics","article_published_time":"2026-01-06T13:30:38+00:00","article_modified_time":"2026-06-01T14:17:00+00:00","author":"Henrique de Carvalho","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Henrique de Carvalho","Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/#article","isPartOf":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/"},"author":{"name":"Henrique de Carvalho","@id":"https:\/\/9biotx.com\/#\/schema\/person\/eda3764256a793b2350112b46b0169a8"},"headline":"9Bio Therapeutics Approved for Highest Microsoft for Startups Credit Tier to Accelerate AI-Enabled Biologics Discovery","datePublished":"2026-01-06T13:30:38+00:00","dateModified":"2026-06-01T14:17:00+00:00","mainEntityOfPage":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/"},"wordCount":403,"publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"articleSection":["News"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/","url":"https:\/\/9biotx.com\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/","name":"9Bio Therapeutics Approved for Highest Microsoft for Startups Credit Tier to Accelerate AI-Enabled Biologics Discovery - 9Bio Therapeutics","isPartOf":{"@id":"https:\/\/9biotx.com\/#website"},"datePublished":"2026-01-06T13:30:38+00:00","dateModified":"2026-06-01T14:17:00+00:00","breadcrumb":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/9biotx.com\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-approved-for-highest-microsoft-for-startups-credit-tier-to-accelerate-ai-enabled-biologics-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/9biotx.com\/"},{"@type":"ListItem","position":2,"name":"9Bio Therapeutics Approved for Highest Microsoft for Startups Credit Tier to Accelerate AI-Enabled Biologics Discovery"}]},{"@type":"WebSite","@id":"https:\/\/9biotx.com\/#website","url":"https:\/\/9biotx.com\/","name":"9Bio Th\u00e9rapeutiques","description":"Engineering Biological Possibilities","publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/9biotx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/9biotx.com\/#organization","name":"9Bio Th\u00e9rapeutiques","url":"https:\/\/9biotx.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/","url":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","contentUrl":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","width":200,"height":80,"caption":"9Bio Therapeutics"},"image":{"@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/9bio\/"]},{"@type":"Person","@id":"https:\/\/9biotx.com\/#\/schema\/person\/eda3764256a793b2350112b46b0169a8","name":"Henrique de Carvalho","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","caption":"Henrique de Carvalho"},"sameAs":["https:\/\/9bio.ca"]}]}},"taxonomy_info":{"category":[{"value":1,"label":"News"}]},"featured_image_src_large":false,"author_info":{"display_name":"Henrique de Carvalho","author_link":"https:\/\/9biotx.com\/fr\/news\/author\/decarvalho\/"},"comment_info":0,"category_info":[{"term_id":1,"name":"News","slug":"news","term_group":0,"term_taxonomy_id":1,"taxonomy":"category","description":"9Bio News","parent":0,"count":8,"filter":"raw","cat_ID":1,"category_count":8,"category_description":"9Bio News","cat_name":"News","category_nicename":"news","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/2408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/comments?post=2408"}],"version-history":[{"count":5,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/2408\/revisions"}],"predecessor-version":[{"id":2414,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/2408\/revisions\/2414"}],"wp:attachment":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/media?parent=2408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/categories?post=2408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/tags?post=2408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}